• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于治疗哮喘/慢性阻塞性肺疾病的血管活性肠肽(VIP)的生物活性类似物及药物递送系统

Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma/COPD.

作者信息

Onoue Satomi, Yamada Shizuo, Yajima Takehiko

机构信息

Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Toho University, Funabashi, Chiba 274-8510, Japan.

出版信息

Peptides. 2007 Sep;28(9):1640-50. doi: 10.1016/j.peptides.2007.04.009. Epub 2007 Apr 22.

DOI:10.1016/j.peptides.2007.04.009
PMID:17537541
Abstract

Vasoactive intestinal peptide (VIP) is one of the major peptide transmitters in the central and peripheral nervous systems, being involved in a wide range of biological functions. In an airway system where VIP-immunoreactive nerve fibers are present, VIP acts as neurotransmitter or neuromodulator of the inhibitory non-adrenergic and non-cholinergic airway nervous system and influences many aspects of pulmonary biology. A clinical application of VIP has been believed to offer potential benefits in the treatment of chronic inflammatory lung diseases such as asthma and chronic obstructive pulmonary disease (COPD), however, its clinical application has been limited in the past for a number of reasons, including its extremely short plasma half-life after intravenous administration and difficulty in administration routes. The development of long-acting VIP analogues, in combination with appropriate drug delivery systems, may provide clinically useful agents for the treatment of asthma/COPD. In this review, development of efficacious VIP derivatives, drug delivery systems designed for VIPs and the potential application for asthma/COPD are discussed. We also include original data from our chemical modification experiments and formulation studies, which led to successful development of [R(15, 20, 21), L(17)]-VIP-GRR (IK312532), a potent VIP analogue, and a VIPs-based dry powder inhaler system.

摘要

血管活性肠肽(VIP)是中枢和外周神经系统中的主要肽类递质之一,参与广泛的生物学功能。在存在VIP免疫反应性神经纤维的气道系统中,VIP作为抑制性非肾上腺素能和非胆碱能气道神经系统的神经递质或神经调节剂,影响肺生物学的许多方面。人们认为VIP的临床应用在治疗慢性炎症性肺病如哮喘和慢性阻塞性肺疾病(COPD)方面具有潜在益处,然而,由于多种原因,其临床应用在过去受到限制,包括静脉给药后血浆半衰期极短以及给药途径困难。长效VIP类似物的开发,结合适当的药物递送系统,可能为哮喘/COPD的治疗提供临床上有用的药物。在这篇综述中,讨论了有效的VIP衍生物的开发、为VIP设计的药物递送系统以及对哮喘/COPD的潜在应用。我们还包括来自我们化学修饰实验和制剂研究的原始数据,这些研究成功开发了一种有效的VIP类似物[R(15, 20, 21), L(17)]-VIP-GRR(IK312532)和一种基于VIP的干粉吸入器系统。

相似文献

1
Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma/COPD.用于治疗哮喘/慢性阻塞性肺疾病的血管活性肠肽(VIP)的生物活性类似物及药物递送系统
Peptides. 2007 Sep;28(9):1640-50. doi: 10.1016/j.peptides.2007.04.009. Epub 2007 Apr 22.
2
Long-acting analogue of vasoactive intestinal peptide, [R15, 20, 21, L17]-VIP-GRR (IK312532), protects rat alveolar L2 cells from the cytotoxicity of cigarette smoke.血管活性肠肽长效类似物[R15, 20, 21, L17]-VIP-GRR(IK312532)可保护大鼠肺泡L2细胞免受香烟烟雾的细胞毒性作用。
Regul Pept. 2004 Dec 15;123(1-3):193-9. doi: 10.1016/j.regpep.2004.04.025.
3
Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors.基于神经肽的药物治疗新观念:血管活性肠肽及其受体
Eur J Pharmacol. 2006 Mar 8;533(1-3):182-94. doi: 10.1016/j.ejphar.2005.12.055. Epub 2006 Feb 10.
4
Formulation design and in vivo evaluation of dry powder inhalation system of new vasoactive intestinal peptide derivative ([R(15, 20, 21), L(17), A(24,25), des-N(28)]-VIP-GRR) in experimental asthma/COPD model rats.新型血管活性肠肽衍生物 ([R(15, 20, 21), L(17), A(24,25), des-N(28)]-VIP-GRR) 在实验性哮喘/COPD 模型大鼠干粉吸入系统的制剂设计与体内评价。
Int J Pharm. 2011 May 30;410(1-2):54-60. doi: 10.1016/j.ijpharm.2011.03.021. Epub 2011 Mar 16.
5
Inhalable powder formulation of a stabilized vasoactive intestinal peptide (VIP) derivative: anti-inflammatory effect in experimental asthmatic rats.一种稳定的血管活性肠肽(VIP)衍生物的可吸入粉末制剂:在实验性哮喘大鼠中的抗炎作用。
Peptides. 2010 Jan;31(1):72-8. doi: 10.1016/j.peptides.2009.09.032. Epub 2009 Oct 4.
6
Inhalable powder formulation of vasoactive intestinal peptide derivative, [R15,20,21, L17]-VIP-GRR, attenuated neutrophilic airway inflammation in cigarette smoke-exposed rats.可吸入型血管活性肠肽衍生物[R15,20,21, L17]-VIP-GRR 干粉制剂减轻香烟暴露大鼠中性粒细胞性气道炎症。
Eur J Pharm Sci. 2010 Nov 20;41(3-4):508-14. doi: 10.1016/j.ejps.2010.08.007. Epub 2010 Aug 24.
7
Development of dry powder inhalation system of novel vasoactive intestinal peptide (VIP) analogue for pulmonary administration.用于肺部给药的新型血管活性肠肽(VIP)类似物干粉吸入系统的研发。
Life Sci. 2006 Jun 6;79(2):138-43. doi: 10.1016/j.lfs.2005.12.049. Epub 2006 Feb 3.
8
Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review.COPD/PAH 和哮喘的血管活性肠肽治疗前景:综述。
Respir Res. 2011 Apr 11;12(1):45. doi: 10.1186/1465-9921-12-45.
9
Pharmacological effects and lung-binding characteristics of a novel VIP analogue, [R15, 20, 21, L17]-VIP-GRR (IK312532).一种新型VIP类似物[R15, 20, 21, L17]-VIP-GRR(IK312532)的药理作用及肺结合特性
Regul Pept. 2004 Dec 15;123(1-3):201-7. doi: 10.1016/j.regpep.2004.04.029.
10
Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications.血管活性肠肽(VIP)的构效关系:强效激动剂及潜在临床应用
Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6):579-90. doi: 10.1007/s00210-007-0232-0. Epub 2008 Jan 3.

引用本文的文献

1
Dry Powder Inhalers for Delivery of Synthetic Biomolecules.用于递送合成生物分子的干粉吸入器。
Pharmaceuticals (Basel). 2025 Jan 27;18(2):175. doi: 10.3390/ph18020175.
2
Study effect of MAPA-VIP on control of allergic asthma pathophysiology.研究MAPA-VIP对过敏性哮喘病理生理学控制的作用。
Postepy Dermatol Alergol. 2023 Aug;40(4):548-553. doi: 10.5114/ada.2023.129458. Epub 2023 Sep 1.
3
VIP plasma levels associate with survival in severe COVID-19 patients, correlating with protective effects in SARS-CoV-2-infected cells.
VIP 血浆水平与重症 COVID-19 患者的生存相关,与 SARS-CoV-2 感染细胞中的保护作用相关。
J Leukoc Biol. 2022 May;111(5):1107-1121. doi: 10.1002/JLB.5COVA1121-626R. Epub 2022 Mar 24.
4
Regulatory Peptides in Asthma.哮喘中的调节肽。
Int J Mol Sci. 2021 Dec 20;22(24):13656. doi: 10.3390/ijms222413656.
5
Progress in the mechanism and targeted drug therapy for COPD.COPD 的发病机制及靶向药物治疗的研究进展。
Signal Transduct Target Ther. 2020 Oct 27;5(1):248. doi: 10.1038/s41392-020-00345-x.
6
Neuropeptides in asthma, chronic obstructive pulmonary disease and cystic fibrosis.哮喘、慢性阻塞性肺疾病和囊性纤维化中的神经肽。
Respir Res. 2018 Aug 6;19(1):149. doi: 10.1186/s12931-018-0846-4.
7
Neuroendocrine cells derived chemokine vasoactive intestinal polypeptide (VIP) in allergic diseases.神经内分泌细胞衍生趋化因子血管活性肠肽 (VIP) 在过敏性疾病中的作用。
Cytokine Growth Factor Rev. 2017 Dec;38:37-48. doi: 10.1016/j.cytogfr.2017.09.002. Epub 2017 Sep 23.
8
Altered vasoactive intestinal peptides expression in irritable bowel syndrome patients and rats with trinitrobenzene sulfonic acid-induced colitis.肠易激综合征患者及三硝基苯磺酸诱导的结肠炎大鼠中血管活性肠肽表达的改变
World J Gastroenterol. 2015 Jan 7;21(1):155-63. doi: 10.3748/wjg.v21.i1.155.
9
Protective effects of poly (butyl) cyanoacrylate nanoparticles containing vasoactive intestinal peptide against 6-hydroxydopamine-induced neurotoxicity in vitro.含血管活性肠肽的聚氰基丙烯酸丁酯纳米颗粒对6-羟基多巴胺诱导的体外神经毒性的保护作用。
J Mol Neurosci. 2015 Apr;55(4):854-64. doi: 10.1007/s12031-014-0438-9. Epub 2014 Oct 19.
10
Vasodilatory effect of the stable vasoactive intestinal peptide analog RO 25-1553 in murine and rat lungs.RO 25-1553 这种稳定的血管活性肠肽类似物对鼠肺和大鼠肺的血管舒张作用。
PLoS One. 2013 Sep 19;8(9):e75861. doi: 10.1371/journal.pone.0075861. eCollection 2013.